Dr Chihwan David Cha is a breast surgeon and clinician scientist at Hanyang University Hospital in Seoul, South Korea, with specialised expertise in hereditary breast cancer, male breast cancer, and translational research integrating multi-omics data.

He is an active member of the Korean Breast Cancer Study Group (KBCSG) and plays a leading role in the international collaborative research initiatives, including the Oceania-Asia Collaboration Study (OASIS) project.

Dr Cha is a co-principal investigator of the male breast cancer study within the OASIS, which is dedicated to advancing the understanding of male breast cancer in Asian populations.

Through this initiative, he contributes to multinational cohort analyses aimed at elucidating clinicopathologic features, treatment patterns, and long-term survival outcomes across diverse populations.

In parallel, he is a key investigator in the Korea Robot-endoscopic minimal access Breast Surgery Study Group (KoREa-BSG)–led BRCA carrier cohort study, a large-scale, multicenter research program focusing on long-term oncologic outcomes and contralateral breast cancer risk in patients with BRCA1/2 mutations. His research interests include recurrence patterns and long-term surgical outcomes, with the goal of refining risk stratification for BRCA mutation carriers.

In the translational research domain, his work integrates multi-omics approaches with spatial transcriptomic analyses, particularly in triple-negative breast cancer and male breast cancer, to investigate tumor heterogeneity and immune microenvironmental features. He also serves as Executive Secretary of the Surgical Procedure and Technique Committee of the Korean Breast Cancer Society.

In recognition of his research contributions, Dr Cha received the Academic Achievement Award at the Global Breast Cancer Conference (GBCC) in 2025 and was selected for the 2026-2027 ASCO International Clinical Research Scholars Program.